Citing lack of efficacy evidence, the FDA rejected Cytokinetics’ heart failure hopeful omecamtiv mecarbil in a Tuesday evening decision.
Tag Archive for: omecamtiv mecarbil
The U.S. Food and Drug Administration’s panel of outside experts did not lend its support to Cytokinetics Inc.’s heart drug, citing insufficient data on safety and efficacy.